Navigation Links
Neurocrine Biosciences Reports Third Quarter 2012 Results
Date:10/31/2012

SAN DIEGO, Oct. 31, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and nine months ended September 30, 2012. For the third quarter of 2012, the Company reported a net loss of $3.1 million, or $0.05 loss per share, compared to net income of $31.4 million, or income of $0.56 per fully diluted share outstanding, for the same period in 2011. For the nine months ended September 30, 2012, the Company reported a net loss of $4.5 million, or $0.07 loss per share, compared to net income of $36.2 million, or income of $0.64 per fully diluted share outstanding, for the first nine months of last year. During the third quarter of 2011, the Company recognized $30.0 million in milestone revenue under its collaboration agreement with Abbott.

The Company's balance sheet at September 30, 2012 reflected cash, cash equivalents, investments and receivables under collaboration agreements of $185.5 million. 

"Neurocrine continued to advance its development pipeline with our VMAT2 inhibitor entering Phase IIb clinical trials this past quarter," said Christopher O'Brien, Chief Medical Officer of Neurocrine Biosciences. "The KINECT study, along with the pending second Phase IIb study of NBI-98854 in tardive dyskinesia patients as well as information from the elagolix program will provide significant data flow over the coming quarters."

"Significant progress has also been made with elagolix," said Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences. "The Phase III study for elagolix in endometriosis is enrolling as planned, and the Phase II clinical trial in uterine fibroids is anticipated to complete in the first half of next year."

Revenues for the third quarter of 2012 were $9.4 million, compared to $41.6 million for the same period in 2011. Revenues for the nine months ended September 30,
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
2. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
3. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
4. Neurocrine Biosciences Reports Second Quarter 2012 Results
5. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
6. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
7. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
8. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
9. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Selexis SA, a serial innovation company with ... used for drug discovery to commercial manufacturing, announced today ... Next-Generation Sequencing (NGS) data packages. The NGS analysis ... ensuring the integrity of the gene, validation of the ...
(Date:1/22/2015)... , 22 de enero de 2015  El Dr. ... su llamada a nominaciones para 2015. Este prestigioso premio ... o tiene el potencial para hacer, contribuciones destacadas para ... aceptarán hasta el 15 de marzo de 2015 a ...
(Date:1/22/2015)... Medical Systems (NYSE: VAR ), world leader in ... to sustainability with inclusion on a prestigious list of the ... equipment company among the Corporate Knights Global 100 Most Sustainable ... Davos, Switzerland . "We ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5
... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), a ... novel drugs in the,therapeutic areas of infection, cancer and ... founding member of the new NASDAQ OMX,AeA Illinois Tech ... May 19. The,only existing statewide public technology index in ...
... Spinal medical device company Kyphon misled hospitals for ... LLC, formerly known,as Kyphon Inc., has agreed to ... whistleblower lawsuit that exposed the spinal medical device,company,s ... by defrauding,Medicare., The "qui tam" (whistleblower) lawsuit, ...
... May 22 SuperGen, Inc.,(Nasdaq: SUPG ... discovery, rapid,development and commercialization of therapies for ... Michael Molkentin, C.P.A.,Chief Financial Officer and Corporate ... President of Drug Discovery Operations, are scheduled,to ...
Cached Biology Technology:Advanced Life Sciences Selected as Founding Member of the New NASDAQ OMX AeA Illinois Tech Index 2Advanced Life Sciences Selected as Founding Member of the New NASDAQ OMX AeA Illinois Tech Index 3Advanced Life Sciences Selected as Founding Member of the New NASDAQ OMX AeA Illinois Tech Index 4Medtronic Unit to Pay $75 Million to Settle Whistleblower Medicare Fraud Case 2SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008 2
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... the "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Apple introduced the fingerprint reading feature with the iPhone ...
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ...
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced ... audit to confirm its adherence to current U.S. Food ... to conduct regulated smart device and smart phone application ... research quality. "HITLAB is determined to improve ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Mechanism of action of compound found ... The findings may lead researchers to develop ... lateral sclerosis, Huntingtons disease, epilepsy, stroke/ischemia, dementia and ... 2008) Virginia Commonwealth University researchers have discovered ...
... carbon-14 produced by above-ground nuclear testing in the 1950s and ... cells in a human,s body, whether lean or obese, is ... adulthood can be attributed mainly to changes in fat cell ... cells. These results could help researchers develop new pharmaceuticals ...
... of scientists has swapped their comfortable offices for one ... carry out a challenging field campaign that is seen ... ESA,s ice mission CryoSat will be as accurate as ... and Canada, are currently in the middle of CryoSat ...
Cached Biology News:Researchers uncover mechanism of action of antibiotic able to reduce neuronal cell death in brain 2Researchers uncover mechanism of action of antibiotic able to reduce neuronal cell death in brain 3New technique determines the number of fat cells remains constant in all body types 2New technique determines the number of fat cells remains constant in all body types 3Scientists endure Arctic for last campaign prior to CryoSat-2 launch 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 3
... is a compact benchtop and stackable ... controller with a large display screen ... speed. Air circulation inside to evenly ... can be easily calibrated from the ...
... Nonanoyl-N-methylglucamide White ... Can be readily removed by dialysis. ... Purity: ≥98% by HPLC. Absorbance ... 2 O. CMC 19 - ...
...
...
Biology Products: